|Dominik Strzelecki1;Agnieszka Tabaszewska2;Zbigniew Barszcz2;Olga Józefowicz1;Paweł Kropiwnicki3; and Jolanta Rabe-Jabłońska1;
1;Department of Affective and Psychotic Disorders, Medical University of Łódź,
2;Central Clinical Hospital,
3;Department of Adolescent Psychiatry, Medical University of Łódź, Łódź, Poland
Memantine and other glutamatergic agents have been currently investigated in some off-label indications due to glutamatergic involvement in several psychoneurological disorders. We assumed that memantine similarly to ketamine may positively influence mood, moreover having a potential to improve cognition and general quality of life. We report a case of a 49-year-old male hospitalized during a manic and a subsequent moderate depressive episode. After an ineffective use of lithium, olanzapine and antidepressive treatment with mianserin, memantine was added up to 20 mg per day for 10 weeks. The mental state was assessed using the Hamilton Depression Rating Scale, the Young Mania Rating Scale, the Hamilton Anxiety Scale, the Clinical Global Inventory, the World Health Organization Quality of Life Scale and psychological tests. After 10 weeks the patient achieved a partial symptomatic improvement in mood, anxiety and quality of sleep, but his activity remained insufficient. We also observed an improvement in the parameters of cognitive functioning and quality of life. There was neither significant mood variations during the memantine use nor mood changes after its termination. No significant side effects were noted during the memantine treatment. We conclude that using memantine in bipolar depression may improve mood, cognitive functioning and quality of life.
Memantine;Bipolar disorder;Depression;Cognitive functioning;Glutamate.